Respiratory syncytial virus: Current and emerging treatment options

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2014, Pages 217-225

  Turner, Tiffany L ^a   Kopp, Benjamin T ^a   Paul, Grace ^a   Landgrave, Lindsay C ^b   Hayes Jr , Don ^a   Thompson, Rohan ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Bronchiolitis; Lower respiratory tract infection; Probiotics; Respiratory syncytial virus; Vitamin D

Indexed keywords

CATHELICIDIN; CURCUMIN; DINGCHUAN; HERBACEOUS AGENT; IMMUNOGLOBULIN; MEDI 534 VACCINE; MOTAVIZUMAB; PALIVIZUMAB; PREBIOTIC AGENT; PROBIOTIC AGENT; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS VACCINE; VITAMIN D;

ALTERNATIVE MEDICINE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HUMAN; INFECTION PREVENTION; PATIENT CARE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

EID: 84899632970     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s60710     Document Type: Review

References (61)

1. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331-379.
2. Respiratory Syncytial Virus (RSV) Season, U.S., 2011-2012. Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/features/dsrsv/. Accessed March 28, 2014.
3. Protect Against Respiratory Syncytial Virus. Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/features/rsv/. Accessed March 28, 2014.
4. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541-545.
5. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137-141.
6. Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2000;(2):CD001266.
7. Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. J Pediatr. 1990;117(4):633-637.
8. Hartling L, Wiebe N, Russell K, Patel H, Klassen TP. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2004;(1):CD003123.
9. Patel H, Platt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2004;(3):CD004878.
10. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics. 2000;105(4):E44.
11. Respiratory Syncytial Virus Infection (RSV). Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/rsv/research/us-surveillance.html. Accessed March 28, 2014.
12. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774-1793.
13. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5): 1215-1224.
14. Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr. 2010;6(4): 296-300.
15. Santos RP, Chao J, Nepo AG, et al. The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia. Pediatrics. 2012;130(6):e1695-e1699.
16. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J. 2007;26(12):1089-1093.
17. Danziger-Isakov LA, Arslan D, Sweet S, Benden C, Goldfarb S, Wong J. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative. Pediatr Transplant. 2012;16(6):638-644.
18. McCoy D, Wong E, Kuyumjian AG, Wynd MA, Sebti R, Munk GB. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transpl Infect Dis. 2011;13(2):117-121.
19. Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH, Connor EM; MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23(8):707-712.
20. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652-665.
21. Lowry F. FDA panel nixes licensing request for motavizumab [webpage on the Internet]. New York, NY: Medscape; 2010. Available from: http://www.medscape.com/viewarticle/722903. Accessed January 10, 2014.
22. Lagos R, DeVincenzo JP, Muñoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J. 2009;28(9):835-837.
23. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J. 2009;28(7):655-658.
24. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull. 1986;16(1):7.
25. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972;177(4050):705-706.
26. Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA. 1983;249(19):2666-2670.
27. Ribavirin for severe RSV infection. N Engl J Med. 1991;325(26): 1884-1886.
28. Krilov LR. Safety issues related to the administration of ribavirin. Pediatr Infect Dis J. 2002;21(5):479-481.
29. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2007;(1):CD000181.
30. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis. 2013;57(12):1731-1741.
31. Edell D, Khoshoo V, Ross G, Salter K. Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity. Chest. 2002;122(3):935-939.
32. Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31(8):839-844.
33. Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28(1):67-71.
34. Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24(12): 2114-2119.
35. Fuehner T, Dierich M, Duesberg C, et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther. 2011;16(5):733-740.
36. Hemming VG, Prince GA, Horswood RL, et al. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis. 1985;152(5):1083-1087.
37. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother. 1987;31(12): 1882-1886.
38. Sandritter TL, Kraus DM. Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: part I. J Pediatr Health Care. 1997;11(6):284-291; quiz 292.
39. Rodriguez WJ, Gruber WC, Welliver RC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 1997;99(3):454-461.
40. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics. 1998;102(5):1211-1216.
41. Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immune globulin: decisions and costs. Pediatr Pulmonol. 2001;32(1):20-28.
42. Fuller HL, Del Mar CB. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev. 2006;(4):CD004883.
43. Gupta N, LeGoff J, Chamat S, et al. Aff inity-purif ied respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. PLoS One. 2013;8(7):e69390.
44. Kovach MA, Ballinger MN, Newstead MW, et al. Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. J Immunol. 2012;189(1): 304-311.
45. Barlow PG, Svoboda P, Mackellar A, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 2011;6(10):e25333.
46. Mansbach JM, Piedra PA, Borregaard N, et al. Serum cathelicidin level is associated with viral etiology and severity of bronchiolitis. J Allergy Clin Immunol. 2012;130(4):1007-1008.
47. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol. 2008;181(10):7090-7099.
48. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihy-droxyvitamin D(3). J Cyst Fibros. 2007;6(6):403-410.
49. Currie SM, Findlay EG, McHugh BJ, et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One. 2013;8(8):e73659.
50. Steinmann J, Halldórsson S, Agerberth B, Gudmundsson GH. Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother. 2009;53(12):5127-5133.
51. McNally JD, Sampson M, Matheson LA, Hutton B, Little J. Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis. Pediatr Pulmonol. Epub September 9, 2013.
52. Belderbos ME, Houben ML, Wilbrink B, et al. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011;127(6):e1513-e1520.
53. Camargo CA, Ganmaa D, Frazier AL, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics. 2012;130(3):e561-e567.
54. Luoto R, Ruuskanen O, Waris M, Kalliomäki M, Salminen S, Isolauri E. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J Allergy Clin Immunol. Epub October 13, 2013.
55. Kumpu M, Lehtoranta L, Roivainen M, et al. The use of the probiotic Lactobacillus rhamnosus GG and viral findings in the nasopharynx of children attending day care. J Med Virol. 2013;85(9):1632-1638.
56. O'Sullivan-Coyne G, O'Sullivan GC, O'Donovan TR, Piwocka K, McKenna SL. Curcumin induces apoptosis-independent death in oesophageal cancer cells. Br J Cancer. 2009;101(9):1585-1595.
57. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40-59.
58. Obata K, Kojima T, Masaki T, et al. Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells. PLoS One. 2013;8(9):e70225.
59. Choudhary ML, Anand SP, Wadhwa BS, Chadha MS. Genetic variability of human respiratory syncytial virus in Pune, Western India. Infect Genet Evol. 2013;20:369-377.
60. Li L, Yu CH, Ying HZ, Yu JM. Antiviral effects of modified dingchuan decoction against respiratory syncytial virus infection in vitro and in an immunosuppressive mouse model. J Ethnopharmacol. 2013;147(1): 238-244.
61. Villenave R, Thavagnanam S, Sarlang S, et al. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A. 2012;109(13):5040-5045.